Veracyte Inc VCYT:NASDAQ

Last Price$29.62Cboe Real-Time Last Sale as of 10:09AM ET 7/19/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.11(0.37%)
Bid (Size)$29.56 (100)
Ask (Size)$29.74 (100)
Day Low / High$29.50 - 29.78
Volume18.5 K
 

View Biotechnology IndustryPeer Comparison as of 07/19/2019

 

Veracyte Inc ( NASDAQ )

Price: $29.62
Change: +0.11 (0.37%)
Volume: 18.5 K
10:09AM ET 7/19/2019
 
 

Sangamo Therapeutics Inc ( NASDAQ )

Price: $11.92
Change: -0.23 (1.89%)
Volume: 111.7 K
10:09AM ET 7/19/2019
 
 

AnaptysBio Inc ( NASDAQ )

Price: $53.33
Change: +0.33 (0.62%)
Volume: 6.8 K
10:03AM ET 7/19/2019
 
 

Eidos Therapeutics Inc ( NASDAQ )

Price: $36.10
Change: -0.23 (0.63%)
Volume: 10.7 K
10:05AM ET 7/19/2019
 
 

Fate Therapeutics Inc ( NASDAQ )

Price: $22.09
Change: -0.41 (1.82%)
Volume: 63.1 K
10:09AM ET 7/19/2019
 

Read more news Recent News

Analyst Actions: Needham Starts Veracyte at Buy, Price Target is $33
9:09AM ET 7/02/2019 MT Newswires

Veracyte (VCYT) has an average rating among analysts of buy, with an average price target of $18 Price: 28.75, Change: +0.24, Percent Change: +0.84 ...

Veracyte COO To Retire
4:09AM ET 7/01/2019 MT Newswires

Veracyte (VCYT) said in a Friday regulatory filing that Christopher Hall intends to retire as COO, effective July 1. Keith Kennedy, the company's current...

Veracyte Says Cancer Cytopathology Details Co.'s Role in Reducing 'Unnecessary' Surgeries in Thyroid Cancer Diagnosis
2:56PM ET 6/17/2019 MT Newswires

Veracyte (VCYT) said Monday a review article in Cancer Cytopathology, a journal of the American Cancer Society, describes how the technology behind...

Veracyte Seeks $136 Mln From Share Sale at 3.8% Discount for Potential Acquisitions, Debt Payment
8:46AM ET 5/03/2019 MT Newswires

Veracyte Inc. (VCYT) late Thursday said it plans to raise $127.9 million selling 5.5 million shares at $23.25 apiece, or 3.8% below Thursday's close....

Company Profile

Business DescriptionVeracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
Address6000 Shoreline Court
South San Francisco, California 94080
Phone+1.650.243.6300
Number of Employees270
Recent SEC Filing07/11/20194
Chief Operating & Financial OfficerKeith Kennedy
Chief Scientific & Medical OfficerGiulia C. Kennedy
Chief Information OfficerAshish Kheterpal
Executive Vice President & General CounselJulie A. Brooks

Company Highlights

Price Open$29.51
Previous Close$29.51
52 Week Range$8.77 - 30.25
Market Capitalization$1.2 B
Shares Outstanding41.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement07/30/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.42
Beta vs. S&P 500N/A
Revenue$92.0 M
Net Profit Margin-15.51%
Return on Equity-23.43%

Analyst Ratings as of 07/12/2019

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset